RecruitingNot applicableNCT07360808

Safety and Efficacy of Adipose-Derived Regenerative Cells (ADRCs) for Improving Hand Dysfunction in Systemic Sclerosis

Studying Systemic sclerosis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Cytori Therapeutics
Intervention
Autologous ADRCs injection Combined with Standard Therapy(device)
Enrollment
48 enrolled
Eligibility
18-70 years · All sexes
Timeline
2025 – 2027

Study locations (2)

Collaborators

Huashan Hospital · Nanfang Hospital, Southern Medical University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07360808 on ClinicalTrials.gov

Other trials for Systemic sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Systemic sclerosis →

← Back to all trials